Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Exubera: So far no evidence available of an additional therapeutic benefit

10.05.2006


IQWiG publishes a comparative review of inhaled insulin versus insulin administered subcutaneously



There is currently no evidence available that inhaled insulin (Exubera) in diabetes therapy shows advantages over short-acting human insulin or insulin analogues administered subcutaneously. The available studies do not provide evidence that Exubera would improve the quality of life or treatment satisfaction of diabetes patients in Germany. However, they do provide indications of disadvantages of Exubera therapy, for example, an increase in severe hypoglycaemia rates. This is the result of the first Rapid Report produced by the Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG) on 4 May 2006, which was commissioned by the Federal Joint Committee on 17 November 2005.

For this Rapid Report, outcomes were selected which enabled the comparison of Exubera versus insulin administered subcutaneously with regard to patient-relevant endpoints. The endpoints assessed included quality of life, treatment satisfaction, glycaemic control (changes in HbA1c values), hypoglycaemia rates, adverse drug effects, and prevention of late complications.


Possible higher risk of severe hypoglycaemia with Exubera therapy

No studies were identified in which inhaled insulin was compared with insulin administered subcutaneously in patients with type 2 diabetes, within an identical therapeutic regime. In the only comparator study identified, the therapeutic regimes investigated were different (intensified versus conventional insulin therapy). In this study, even though the reductions in blood glucose levels were comparable between treatment groups, a tendency towards a higher incidence of severe hypoglycaemia was shown in patients treated with Exubera.

According to current knowledge, Exubera is not a safe alternative, either, for patients with type 1 diabetes. IQWiG’s comprehensive literature search only identified two studies in which inhaled insulin was compared with insulin administered subcutaneously, within an identical therapeutic regime (intensified insulin therapy). These studies also showed a higher incidence of severe hypoglycaemia in patients treated with Exubera (even though the reductions in blood glucose levels were comparable between treatment groups).

Long-term risks of Exubera therapy unclear

With regard to adverse drug effects, a higher incidence of cough and formation of insulin antibodies was shown with Exubera therapy. On the basis of the data available, it cannot be excluded that long-term Exubera therapy may lead to pulmonary damage. On the contrary: inconsistent study results and the Summary of Product Characteristics provided by the European Medicines Agency (EMEA) in fact indicate a risk potential of Exubera. People who smoke or suffer from pulmonary diseases have so far been excluded from participating in studies on Exubera.

No valid statements on treatment satisfaction and quality of life

Although it is possible to reduce the number of subcutaneous injections with Exubera, they cannot be totally avoided, if the additional administration of basal insulin is necessary. Moreover, regular self-measurement of blood glucose levels by skin prick is still necessary. It cannot be inferred from the studies available that this new way of administering insulin generally improves treatment satisfaction or quality of life in affected patients. On the one hand, these aspects were not or were only insufficiently described in the available publications, although the respective parameters were investigated. On the other hand, the relevance of the available data is limited with regard to Germany, as it appears that Exubera was not compared with insulin administered subcutaneously with pen systems (which is a widespread type of administration in Germany). Instead, it appears that Exubera was compared with insulin administered subcutaneously with syringes for self-filling.

IQWiG does not see its Rapid Report as a conclusive evaluation. IQWiG recommends further evaluations of Exubera and the consideration of previously unpublished data from studies in a next step, provided that the manufacturer supplies them. Furthermore, open issues need to be clarified in an adequately designed randomised intervention study before Exubera is widely prescribed in Germany.

Background on Rapid Reports

The assignment to assess the therapeutic benefit of inhaled insulin was conducted in an accelerated manner by means of a Rapid Report. In contrast to the conventional procedure, a preliminary report is not published during the production of a Rapid Report. A preliminary version of the Rapid Report is reviewed by an external expert. A scientific hearing where interested parties can provide comments is however not conducted. Furthermore, as timelines for publication do not need to be adhered to, the whole procedure is less time-consuming. Primarily, a Rapid Report serves to help the Federal Joint Committee and other organisations form an opinion on a topic. The Federal Joint Committee issues directives for health care services (including the prescription of pharmaceuticals) reimbursed by the statutory health insurance (SHI) funds.

Dr. Anna-Sabine Ernst | EurekAlert!
Further information:
http://www.iqwig.de

More articles from Studies and Analyses:

nachricht Innovative genetic tests for children with developmental disorders and epilepsy
11.07.2018 | Christian-Albrechts-Universität zu Kiel

nachricht Oxygen loss in the coastal Baltic Sea is “unprecedentedly severe”
05.07.2018 | European Geosciences Union

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Future electronic components to be printed like newspapers

A new manufacturing technique uses a process similar to newspaper printing to form smoother and more flexible metals for making ultrafast electronic devices.

The low-cost process, developed by Purdue University researchers, combines tools already used in industry for manufacturing metals on a large scale, but uses...

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

A smart safe rechargeable zinc ion battery based on sol-gel transition electrolytes

20.07.2018 | Power and Electrical Engineering

Reversing cause and effect is no trouble for quantum computers

20.07.2018 | Information Technology

Princeton-UPenn research team finds physics treasure hidden in a wallpaper pattern

20.07.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>